TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of Complete Remission (CR) and Partial Remission (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Success or Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Success or Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall score to the AQ (Autism Quotient) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SRS (Social Reciprocity Scale) score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of Participants With Withdrawals Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Neurodevelopmental assessment at age 4 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tobacco use abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Interleukin (IL)-4 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of subjects with Immediate reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with Immediate reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Light sleep length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep sleep length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD73 expression on T helper lymphocyte subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of a single intradermal injection
Endpoint domain: Adverse events/effects
Primary endpoint: Any Reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: Baker III, IV Capsular Contracture
Endpoint domain: Adverse events/effects
Primary endpoint: Explantation with or without replacement
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Service Access
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinically Important Improvement in ACQ-7 Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perioperative myocardial infarction (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dry eyes symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Level of Marginal Bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pink Esthetic Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral Health Impact Profile 14
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum Bactericidal Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Suicidal Ideation Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved motor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: main objective
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Disease control rate (DCR)
Endpoint domain: Mortality/survival
Primary endpoint: Plasma Concentration 24 Hours Post-dose (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Oral Clearance (CLT/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Oral Clearance Adjusted for Body Weight (CLT/F/kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growing enough tumor infiltrating lymphocytes (TIL) for patient treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of D-mannitol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum observed plasma concentration (Tmax) of Levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC) of Levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural brain abnormalities observed on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of flank fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Walking Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Central Macular Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Macular Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in peritoneal dialysis adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CTC isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CA 125 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to obatoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of mothers and infants non-retained in care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: S100-ß levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With a Score of 0 or 1 on GAAS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Inflammatory Facial Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Noninflammatory Facial Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in bowel wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of pulmonary hypertensive crises
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Six Month Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Amount of stone formation in artificial urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bacteria isolated from non-infection kidney stone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bone densitometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ionized calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in daily pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Are Responder50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Are Responder25
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Experiencing a Grade 3 or Higher Adverse Event (AE) That is Related to Study Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Dose-normalized AUC 0-12wk of SAR441236
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Plasma HIV-1 RNA (log10 Copies/mL) From Baseline to Day 7 of SAR441236 Monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of musculoskeletal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Physical Quality of Life Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of positive bacterial growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time lapse to the first bacterial colonies appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in severity of insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in symptoms of insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants With at Least One Event of Venous Thromboembolism (VTE) and/or Death From Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: change in anti HBs immunoglobins in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in cytokines blood concentrations following vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BOLD activity during fMRI-NF task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in NOSE Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VAS of Nasal Obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of repair of eardrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Morphological changes of aneurysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of clevidipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: development of white spot lesion (WSL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: total system delay to intraarterial thrombectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total system delay to intravenous thrombolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: percentage of individuals scheduling colonoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Intraoperative Case Time With Heart Rate (HR) <60 or >80 Bpm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Postoperative First Three Hours With Heart Rate (HR) <60 or >80 Bpm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Postoperative Hours 4 to 12 With Heart Rate (HR) <60 or >80 Bpm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DHT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in BAT activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of treatment for intrauterine adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Minutes Spent Doing Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of intravenous antiinfective therapy until switching
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in Sepsis Six Bundle implementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCN Function (Circuitry and Performance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCN Function (Self-Report- Disability)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CCN Function (Self-Report- Depressive Symptoms)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ultrasonographic hepato-renal index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurochemical response changes to GABAergic stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of neuroinflammation by measuring Glutathione as a marker of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in percent-correct performance in the respective training task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity (the smallest letter the participants can see)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensitivity for identifying single letters (the lowest contrast required to identify letters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crowding extent (the extent over which adjacent letters will affect the recognition of a letter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of ovarian hyperstimulation syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Time Spent With Blood Glucose < 3.9 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Time Spent in Target Range (70-180 mg/dl or 3.9-10.0 mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Characterization of meningitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients achieving favorable outcomes (mRS 0-2 at 90 days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Drug Related Problems (DRP) related to oral anticancer drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of extra-prostatic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neurofilament - light chain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete wound clearing of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Progression free survival (PFS) time in C2C2 patients
Endpoint domain: Mortality/survival
Primary endpoint: Progression free survival (PFS) time in C1 patients
Endpoint domain: Mortality/survival
Primary endpoint: Change in Urinary Domain of the Expanded Prostate Cancer Index (EPIC)
Endpoint domain: Life impact
Endpoint subdomain: Urinary outcomes
Primary endpoint: Change in Bowel Domain of the Expanded Prostate Cancer Index (EPIC)
Endpoint domain: Life impact
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Speed of Processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Global Cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum Plasma Concentration (Cmax) for Zolpidem Tartrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Zolpidem Tartrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)] for Zolpidem Tartrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriologic response (eradication or persistence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pathologic conclusion accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wechsler Memory Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Were Completely Weaned Off PS at End of Study (EOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-day Treatment Failure
Endpoint domain: Mortality/survival
Primary endpoint: Isolation of cancer stem cell populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: visual function of macula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life RAND-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disability level EDSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue level FSS
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Frequency of use of broad-spectrum antifungals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Myoma size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients free of antiarrhythmic medications and free of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of non-fatal myocardial infarction, non-fatal ischemic stroke, non-central nervous system systemic embolization and cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of any bleeding episode requiring in-hospital medical attention and/or a switch of antithrombotic medication
Endpoint domain: Adverse events/effects
Primary endpoint: Change in sweat production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of pH measurement of gastric fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Patients Who Have Responded
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3 or greater toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and quality of engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of HGSOC organoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in rate of advance directive completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in rate of completed advance directives uploaded to electronic medical record
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Assessment of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue medication usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient interest in impairment-directed interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patients global quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Neck Pain Numeric Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occurrence of Multiple Sclerosis (MS)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of severe acute malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brain progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Feeding practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death due to cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Ventricular volume at different shunt settings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Timed Up and Go test at different shunt settings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of 10m walking test at different shunt settings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of therapy (yes, no)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to therapy (yes, no)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety as measured by Physical examination, adverse events, vital signs, and laboratory tests
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the clinician reported photonumeric score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the patient reported global abdominal perception score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain/Enjoyment of Life/General Activity
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Score on the Drug Effects Questionnaire (DEQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Scores on the Marijuana Craving Questionnaire-Short Form (MCQ-SF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for non-invasive ventilation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Length of time on non-invasive ventilation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in peripheral chemoreflex sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of physical or mental state of health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of consumption of street heroin and no increase of cocaine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay in cicatrisation at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes